Board certified in Internal Medicine, Pulmonary Disease, and Critical Care Medicine
Areas of Interest: Ventilator associated pneumonia, pulmonary fibrosis, pulmonary hypertension and lung transplantation
Pulmonary and Critical Care Fellowship: Washington University, St. Louis, MO
Residency: Memorial Medical Center, Savannah, GA
Medical School: University of Iowa, College of Medicine, Iowa City, IA
Master of Science: University of Michigan, Ann Arbor, MI
Medicine
Professor
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed, Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated with Pulmonary Fibrosis on Long
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)
Ready 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
A Multicenter, Randomised, Double-Blind, Chronic-Dosing, Parallel-Group, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with
A Study to Test How Taking B1 1015550 for 12 Weeks Affects Lung Function in People with Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Selection Study of S-600918 in Patients with Refractory Chronic Cough
INS-415 - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments and Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adul
INS-416 - ENCORE - A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberc
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard of Care Antibiotics for the Treatment of Staphylococcus Aureus Bloodstream Infections (Bacteremia), Includin
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 Weeks in Subjects with Idiopathic Pulmonary Fibrosi
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, I 2-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)" MK-7264-030-0024
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer 2016-01
Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program 2016-11
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
A Protocol Comparing Temporary Transvenous Diaphragm Pacing to Standard of Care for Weaning from Mechanical Ventilation in ICU Patients (RESCUE 3): A Randomized, Controlled, Open-Label, Multi-Center Adaptive Clinical Trial to Investigate the Safe and Effe
An Open-Label Extension Trial of The Long-Term Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF_ILD)
1305-0023 A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
MK-5475-013-0123 - A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
LIGHTHOUSE - Roche Cancer Screening Collection Study
A Randomized, Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of Rayaldee (Calcifediol) Extended-release Capsules to Treat Symptomatic Patients Infected with SARS-CoV-2 (REsCue)
Ready 1: A Phase 3, Randomized, Double-Blind, Active and Placebo-controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis - The ASPEN Study
A Study to Test How Taking B1 1015550 for 12 Weeks Affects Lung Function in People with Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Selection Study of S-600918 in Patients with Refractory Chronic Cough
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, I 2-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough (PN030)" MK-7264-030-0024
Blood Sample Collection in Subjects with Pulmonary Nodules or CT Suspicion of Lung Cancer 2016-01
Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program 2016-11
A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase 2b Study to Evaluate the Efficacy and Safety of Multiple Doses of BLU-5937 in Adult Participants With Refractory Chronic Cough
An Open-Label Extension Trial of The Long-Term Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF_ILD)
1305-0023 A Double Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
MK-5475-013-0123 - A Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
LIGHTHOUSE - Roche Cancer Screening Collection Study